US Patent 10077318 Cysteine engineered antibodies and conjugates
Patent 10077318 was granted and assigned to Genentech on September, 2018 by the United States Patent and Trademark Office.
All edits
Edits on 26 Jun, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 8 Dec, 2023
Golden AI
Edits made to:
Article (+386 characters)
Article
Patent abstract
Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody.
Edits on 30 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
100773180
Date of Patent
September 18, 2018
0Patent Application Number
148513480
Date Filed
September 11, 2015
0Patent Primary Examiner
Edits on 25 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
100773180
Date of Patent
September 18, 2018
0Patent Application Number
148513480
Date Filed
September 11, 2015
0Patent Primary Examiner
Edits on 22 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 10077318 Cysteine engineered antibodies and conjugates
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10077318
Date of patent
September 18, 2018
Patent application number
14851348
Date Filed
September 11, 2015
Patent primary examiner
Find more entities like US Patent 10077318 Cysteine engineered antibodies and conjugates
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.